Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/32361

Registo completo
Campo DCValorIdioma
dc.contributor.authorPacheco, Daniela P.por
dc.contributor.authorAmaral, Maria H.por
dc.contributor.authorReis, R. L.por
dc.contributor.authorMarques, A. P.por
dc.contributor.authorCorrelo, V. M.por
dc.date.accessioned2015-01-06T10:23:36Z-
dc.date.available2015-01-06T10:23:36Z-
dc.date.issued2015-01-
dc.date.submitted2014-12-
dc.identifier.citationPacheco D. P., Amaral M. H., Reis R. L., Marques A. P., Correlo V. M. Development of an injectable PHBV microparticles-GG hydrogel hybrid system for regenerative medicine, International Journal of Pharmaceutics, Vol. 478, Issue 1, pp. 398-408, doi:10.1016/j.ijpharm.2014.11.036, 2015por
dc.identifier.issn0378-5173por
dc.identifier.urihttps://hdl.handle.net/1822/32361-
dc.description.abstractUncontrollable displacements that greatly affect the concentration of active agents at the target tissues are among a major limitation of the use of microparticulate drug delivery systems (DDS). Under this context a biphasic injectable DDS combining poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) microparticles (MPs) and a gellan gum (GG) injectable hydrogel is herein proposed for the localized delivery and long-term retention of MPs carrying hydrophilic and hydrophobic model active agents. A double emulsion-solvent evaporation method was adopted to develop the PHBV MPs, carrying bovine serum albumin (BSA) or dexamethasone (Dex) as hydrophilic and hydrophobic active agents’ models, respectively. Moreover, this method was modified, together with the properties of the hydrogel to tailor the delivery profile of the active agents. Variations of the composition of the organic phase during the process allowed tuning surface topography, particle size distribution and core porosity of the PHBV MPs and, thus, the in vitro release profile of Dex but not of BSA. Besides, after embedding hydrogels of higher GG concentration led to a slower and more sustained release of both active agents, independently of the processing conditions of the microparticulate system.por
dc.description.sponsorshipThe authors would like to acknowledge the Project RL1 - ABMR - NORTE-01-0124-FEDER-000016 co-financed by North Portugal Regional Operational Programme (ON.2 - O Novo Norte), under the National Strategic Reference Framework (NSRF), through the European Regional Development Fund (ERDF). This work was partially supported by European Research Council grant agreement ERC-2012-ADG 20120216-321266 for project ComplexiTE.por
dc.language.isoengpor
dc.publisherElsevierpor
dc.rightsopenAccesspor
dc.subjectGellan Gumpor
dc.subjectInjectable hydrogelpor
dc.subjectMicroparticulate systemspor
dc.subjectPolyhydroxybutyrate-co-hydroxyvaleratepor
dc.subjectRegenerative medicinepor
dc.titleDevelopment of an injectable PHBV microparticles-GG hydrogel hybrid system for regenerative medicinepor
dc.typearticle-
dc.peerreviewedyespor
dc.relation.publisherversionhttp://www.sciencedirect.com/science/article/pii/S0378517314008485por
dc.commentshttp://www.3bs.uminho.pt/node/18245por
sdum.publicationstatuspublishedpor
oaire.citationStartPage398por
oaire.citationEndPage408por
oaire.citationIssue1por
oaire.citationTitleInternational Journal of Pharmaceuticspor
oaire.citationVolume478por
dc.date.updated2014-12-22T14:26:09Z-
dc.identifier.doi10.1016/j.ijpharm.2014.11.036por
dc.identifier.pmid25448558por
dc.subject.wosScience & Technologypor
sdum.journalInternational Journal of Pharmaceuticspor
Aparece nas coleções:3B’s - Artigos em revistas/Papers in scientific journals

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
18245-Development of an injectable PHBV microparticles-GG hydrogel hybrid system for regenerative medicine.pdf2,37 MBAdobe PDFVer/Abrir

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID